|
시장보고서
상품코드
2067669
세포치료 모니터링 키트 시장 규모, 점유율 및 동향 분석 보고서 : 제품 유형별, 용도별, 치료법별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)Cell Therapy Monitoring Kits Market Size, Share & Trends Analysis Report By Product (Cell Activation Kit, Stem Cell Kit), By Application (Oncology, Autoimmune Diseases), By Therapy Type, By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
세포 치료 모니터링 키트 시장 개요
세계의 세포치료 모니터링 키트 시장 규모는 2025년에 14억 달러로 추계되며, 2033년까지 25억 달러에 달할 것으로 예측됩니다.
2026-2033년 연평균 성장률(CAGR) 7.6%로 성장할 것으로 전망됩니다. 이 시장의 성장은 세포 치료의 도입 확대와 품질 모니터링에 대한 수요 증가에 힘입어 이루어지고 있습니다.
세포·유전자 치료의 급속한 확대
세포·유전자 치료 파이프라인이 급속히 확대되고 있는 것이 세포 치료 모니터링 키트 시장의 주요 성장 동력이 되고 있습니다. 키메라 항원 수용체 T세포(CAR-T) 치료, 줄기세포 치료, 유전자 편집 치료 등 첨단 치료법들이 임상 단계 및 상용화 단계에서 진전을 보이고 있습니다. 승인 및 임상시험이 늘어남에 따라 신뢰성이 높은 모니터링 솔루션에 대한 수요가 높아지고 있으며, 개발 및 제조의 각 단계에 마련된 여러 점검 지점을 통해 키트의 지속적인 사용이 촉진되고 있습니다.
또한 세포 치료에서는 세포의 분리, 변형, 증식, 투여와 같은 전 과정에 걸쳐 엄격한 평가가 요구됩니다. 규제 기준을 충족하고 안전성을 확보하기 위해서는 생존율, 순도, 동일성, 효능 등의 매개변수를 지속적으로 모니터링해야 합니다. 이러한 치료법은 공정의 변동에 민감하므로 배치별 실시간 모니터링이 필요하며, 그 결과 검사 빈도가 증가하고 전용 모니터링 키트의 도입이 확대되고 있습니다.
엄격한 규제 요건(GMP, FDA, EMA)
엄격한 규제 요건은 세포 치료 모니터링 키트 시장의 주요 성장 동인이 되고 있습니다. 세포 치료제는 살아있는 제품이며 변동이 심하므로 미국 식품의약국(FDA)이나 유럽의약품청(EMA) 등의 규제 당국은 품질관리, 안전성, 유효성에 관해 엄격한 지침을 시행하고 있습니다. 제조업체는 우수 제조 기준(GMP) 및 우수 시험실 기준(GLP) 등의 지침을 준수해야 하며, 이러한 기준은 개발 및 제조의 모든 단계에 걸쳐 포괄적인 모니터링을 요구하고 있습니다.
이러한 기준을 충족하기 위해서는 세포의 동일성, 순도, 효능, 무균성 등 중요한 매개변수에 대한 지속적인 평가가 필수적입니다. 모니터링 키트는 로트 간 균일성, 추적성 및 규정 준수를 보장하는 데 있으며, 매우 중요한 역할을 수행하며, 제품의 결함이나 부적합 위험을 줄여줍니다. 치료법 승인이 늘어남에 따라 규제 당국의 감독이 강화되는 가운데, 첨단 모니터링 솔루션에 대한 의존도는 계속해서 높아지고 있으며, 이것이 시장의 지속적인 수요를 견인하고 있습니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 세포치료 모니터링 키트 시장 : 변수, 동향, 범위
제4장 세포치료 모니터링 키트 시장 : 제품별 추정·동향 분석
제5장 세포치료 모니터링 키트 시장 : 용도별 추정·동향 분석
제6장 세포치료 모니터링 키트 시장 : 요법 유형별 추정·동향 분석
제7장 세포치료 모니터링 키트 시장 : 최종 사용별 추정·동향 분석
제8장 세포치료 모니터링 키트 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSACell Therapy Monitoring Kits Market Summary
The global cell therapy monitoring kits market size was estimated at USD 1.4 billion in 2025 and is projected to reach USD 2.5 billion by 2033, growing at a CAGR of 7.6% from 2026 to 2033. The market growth is driven by the rising adoption of cell therapies and the increasing need for quality monitoring.
Rapid growth of cell & gene therapies
The rapid expansion of the cell and gene therapy pipeline is a key driver of the cell therapy monitoring kits market. Advanced modalities such as chimeric antigen receptor T-cell (CAR-T) therapy, stem cell therapies, and gene-edited treatments are advancing across clinical and commercial stages. As approvals and clinical trials increase, the demand for reliable monitoring solutions rises, with multiple checkpoints across development and manufacturing driving consistent kit usage.
In addition, cell therapies require strict evaluation throughout processes such as cell isolation, modification, expansion, and infusion. Parameters, including viability, purity, identity, and potency, must be continuously monitored to meet regulatory standards and ensure safety. Due to their sensitivity to process variations, these therapies require real-time, batch-specific monitoring, leading to higher testing frequency and greater adoption of specialized monitoring kits.
Strong Regulatory Requirements (GMP, FDA, EMA)
Stringent regulatory requirements are a major driver of the cell therapy monitoring kits market. As cell therapies are living, highly variable products, regulatory bodies such as the U.S. Food and Drug Administration and the European Medicines Agency enforce strict guidelines for quality control, safety, and efficacy. Manufacturers must comply with frameworks like Good Manufacturing Practice and Good Laboratory Practice, which require comprehensive monitoring at every stage of development and production.
To meet these standards, continuous assessment of critical parameters such as cell identity, purity, potency, and sterility is essential. Monitoring kits play a crucial role in ensuring batch-to-batch consistency, traceability, and regulatory compliance, reducing the risk of product failure or rejection. As regulatory scrutiny intensifies alongside increasing therapy approvals, the reliance on advanced monitoring solutions continues to grow, driving sustained market demand.
Global Cell Therapy Monitoring Kits Market Report Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the cell therapy monitoring kits market report based on product, application, therapy type, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Cell Activation Kit
- Immune Cell Differentiation and Expansion Kits
- Stem Cell Kit
- Others
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Oncology
- Autoimmune Diseases
- Cardiovascular Diseases
- Neurological Disorders
- Musculoskeletal Disorders
- Others
- Therapy Type Outlook (Revenue, USD Million, 2021 - 2033)
- Stem Cell Therapies
- Chimeric Antigen Receptor (CAR) T-Cell Therapies
- Natural Killer (NK) Cell Therapies
- Others
- End Use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals and Clinics
- Research Institutes
- Biotechnology and Pharmaceutical Companies
- Contract Research Organizations (CROs)
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- MEA
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Application Segment
- 1.2.3. Therapy Type Segment
- 1.2.4. End Use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Model
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Cell Therapy Monitoring Kits Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rapid growth of cell & gene therapies
- 3.2.1.2. Strong regulatory requirements (GMP, FDA, EMA)
- 3.2.1.3. Technological advancements in analytical platforms
- 3.2.1.4. Growth in biopharmaceutical manufacturing and outsourcing
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of monitoring technologies
- 3.2.2.2. Complexity of cell therapy manufacturing
- 3.2.2.3. Limited scalability and workflow integration
- 3.2.3. Market opportunity analysis
- 3.2.4. Market challenge analysis
- 3.2.1. Market driver analysis
- 3.3. Case Study Insights
- 3.4. Cell Therapy Monitoring Kits Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.2. PESTEL Analysis
Chapter 4. Cell Therapy Monitoring Kits Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Cell Therapy Monitoring Kits Market Product Movement Analysis
- 4.3. Global Cell Therapy Monitoring Kits Market Size & Trend Analysis, by Product, 2021 to 2033 (USD Million)
- 4.4. Cell Activation Kit
- 4.4.1. Cell Activation Kit market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Immune Cell Differentiation and Expansion Kits
- 4.5.1. Immune Cell Differentiation and Expansion Kits market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Stem Cell Kit
- 4.6.1. Stem Cell Kit market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Others
- 4.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Cell Therapy Monitoring Kits Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Cell Therapy Monitoring Kits Market Application Movement Analysis
- 5.3. Global Cell Therapy Monitoring Kits Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
- 5.4. Oncology
- 5.4.1. Oncology market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Autoimmune Diseases
- 5.5.1. Autoimmune Diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Cardiovascular Diseases
- 5.6.1. Cardiovascular Diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Neurological Disorders
- 5.7.1. Neurological Disorders market estimates and forecasts 2021 to 2033 (USD Million)
- 5.8. Musculoskeletal Disorders
- 5.8.1. Musculoskeletal Disorders market estimates and forecasts 2021 to 2033 (USD Million)
- 5.9. Others
- 5.9.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Cell Therapy Monitoring Kits Market: Therapy Type Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Cell Therapy Monitoring Kits Market Therapy Type Movement Analysis
- 6.3. Global Cell Therapy Monitoring Kits Market Size & Trend Analysis, by Therapy Type, 2021 to 2033 (USD Million)
- 6.4. Stem Cell Therapies
- 6.4.1. Stem Cell Therapies market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Chimeric Antigen Receptor (CAR) T-Cell Therapies
- 6.5.1. Chimeric Antigen Receptor (CAR) T-Cell Therapies market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Natural Killer (NK) Cell Therapies
- 6.6.1. Natural Killer (NK) Cell Therapies market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Others
- 6.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Cell Therapy Monitoring Kits Market: End Use Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Cell Therapy Monitoring Kits Market End Use Movement Analysis
- 7.3. Global Cell Therapy Monitoring Kits Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 7.4. Hospitals and Clinics
- 7.4.1. Hospitals and Clinics market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Research Institutes
- 7.5.1. Research Institutes market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Biotechnology and Pharmaceutical Companies
- 7.6.1. Biotechnology and Pharmaceutical Companies market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. Contract Research Organizations (CROs)
- 7.7.1. Contract Research Organizations (CROs) market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Cell Therapy Monitoring Kits Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size, & Forecasts Trend Analysis, 2021 to 2033
- 8.4. North America
- 8.4.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.2. U.S.
- 8.4.2.1. Key country dynamics
- 8.4.2.2. Competitive scenario
- 8.4.2.3. Regulatory framework
- 8.4.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.3. Canada
- 8.4.3.1. Key country dynamics
- 8.4.3.2. Competitive scenario
- 8.4.3.3. Regulatory framework
- 8.4.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4.4. Mexico
- 8.4.4.1. Key country dynamics
- 8.4.4.2. Competitive scenario
- 8.4.4.3. Regulatory framework
- 8.4.4.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Europe
- 8.5.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.2. UK
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Competitive scenario
- 8.5.2.3. Regulatory framework
- 8.5.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.3. Germany
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Competitive scenario
- 8.5.3.3. Regulatory framework
- 8.5.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.4. France
- 8.5.4.1. Key country dynamics
- 8.5.4.2. Competitive scenario
- 8.5.4.3. Regulatory framework
- 8.5.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.5. Italy
- 8.5.5.1. Key country dynamics
- 8.5.5.2. Competitive scenario
- 8.5.5.3. Regulatory framework
- 8.5.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.6. Spain
- 8.5.6.1. Key country dynamics
- 8.5.6.2. Competitive scenario
- 8.5.6.3. Regulatory framework
- 8.5.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.7. Norway
- 8.5.7.1. Key country dynamics
- 8.5.7.2. Competitive scenario
- 8.5.7.3. Regulatory framework
- 8.5.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.8. Sweden
- 8.5.8.1. Key country dynamics
- 8.5.8.2. Competitive scenario
- 8.5.8.3. Regulatory framework
- 8.5.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5.9. Denmark
- 8.5.9.1. Key country dynamics
- 8.5.9.2. Competitive scenario
- 8.5.9.3. Regulatory framework
- 8.5.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Asia Pacific
- 8.6.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.2. Japan
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Competitive scenario
- 8.6.2.3. Regulatory framework
- 8.6.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.3. China
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Competitive scenario
- 8.6.3.3. Regulatory framework
- 8.6.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.4. India
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Competitive scenario
- 8.6.4.3. Regulatory framework
- 8.6.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.5. Australia
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Competitive scenario
- 8.6.5.3. Regulatory framework
- 8.6.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.6. South Korea
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Competitive scenario
- 8.6.6.3. Regulatory framework
- 8.6.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6.7. Thailand
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Competitive scenario
- 8.6.7.3. Regulatory framework
- 8.6.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7. Latin America
- 8.7.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.2. Brazil
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Competitive scenario
- 8.7.2.3. Regulatory framework
- 8.7.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 8.7.3. Argentina
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Competitive scenario
- 8.7.3.3. Regulatory framework
- 8.7.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8. MEA
- 8.8.1. Market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.2. South Africa
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Competitive scenario
- 8.8.2.3. Regulatory framework
- 8.8.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key country dynamics
- 8.8.3.2. Competitive scenario
- 8.8.3.3. Regulatory framework
- 8.8.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.4. UAE
- 8.8.4.1. Key country dynamics
- 8.8.4.2. Competitive scenario
- 8.8.4.3. Regulatory framework
- 8.8.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 8.8.5. Kuwait
- 8.8.5.1. Key country dynamics
- 8.8.5.2. Competitive scenario
- 8.8.5.3. Regulatory framework
- 8.8.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Company/Competition Categorization
- 9.2. Strategy Mapping
- 9.3. Company Market Position Analysis, 2025
- 9.4. Company Profiles/Listing
- 9.4.1. STEMCELL Technologies Inc.
- 9.4.1.1. Company overview
- 9.4.1.2. Financial performance
- 9.4.1.3. Product benchmarking
- 9.4.1.4. Strategic initiatives
- 9.4.2. Lonza Group
- 9.4.2.1. Company overview
- 9.4.2.2. Financial performance
- 9.4.2.3. Product benchmarking
- 9.4.2.4. Strategic initiatives
- 9.4.3. Thermo Fisher Scientific Inc.
- 9.4.3.1. Company overview
- 9.4.3.2. Financial performance
- 9.4.3.3. Product benchmarking
- 9.4.3.4. Strategic initiatives
- 9.4.4. Merck KGaA (Sigma-Aldrich)
- 9.4.4.1. Company overview
- 9.4.4.2. Financial performance
- 9.4.4.3. Product benchmarking
- 9.4.4.4. Strategic initiatives
- 9.4.5. BD Biosciences
- 9.4.5.1. Company overview
- 9.4.5.2. Financial performance
- 9.4.5.3. Product benchmarking
- 9.4.5.4. Strategic initiatives
- 9.4.6. Miltenyi Biotec
- 9.4.6.1. Company overview
- 9.4.6.2. Financial performance
- 9.4.6.3. Product benchmarking
- 9.4.6.4. Strategic initiatives
- 9.4.7. GE Healthcare
- 9.4.7.1. Company overview
- 9.4.7.2. Financial performance
- 9.4.7.3. Product benchmarking
- 9.4.7.4. Strategic initiatives
- 9.4.8. Sartorius AG
- 9.4.8.1. Company overview
- 9.4.8.2. Financial performance
- 9.4.8.3. Product benchmarking
- 9.4.8.4. Strategic initiatives
- 9.4.9. PerkinElmer Inc.
- 9.4.9.1. Company overview
- 9.4.9.2. Financial performance
- 9.4.9.3. Product benchmarking
- 9.4.9.4. Strategic initiatives
- 9.4.10. Cell Biolabs Inc.
- 9.4.10.1. Company overview
- 9.4.10.2. Financial performance
- 9.4.10.3. Product benchmarking
- 9.4.10.4. Strategic initiatives
- 9.4.1. STEMCELL Technologies Inc.
